Previous 10 | Next 10 |
home / stock / oryzf / oryzf news
In combination with gilteritinib Primary objectives: to assess safety, tolerability and RP2D Secondary objectives: to assess efficacy MADRID, Spain and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ...
BIO CEO & Investor Conference 2022, New York Epigenetics Symposium – From Genes to Chromatin to Therapeutics BioMed Event 2022, Paris Barclays Global Healthcare Conference, Miami MADRID, Spain and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWI...
LONDON, UK / ACCESSWIRE / February 10, 2022 / Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase 1A, or LSD1, inhibitors). The company's R&D strategy has been to select indications wh...
Oryzon Genomics S.A. press release (OTCPK:ORYZF): GAAP EPS of -$0.04. Cash, cash equivalents and marketable securities totaled $32.5M as of December 31, 2021, compared to $48.6M as of December 31, 2020 For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.04
MADRID, Spain and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for...
Dr. Ana Limón is a specialist in Oncology with extensive industry experience To coordinate global clinical strategy in oncology from Boston, USA MADRID, Spain and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, O...
Serbian arm final deployment in PORTICO Study already active in Spain, Bulgaria, Germany and USA MADRID and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging...
40th Annual J.P. Morgan Healthcare Conference Biotech Showcase 2022 11 th Annual LifeSci Partners Corporate Access Event 2022 H.C. Wainwright Bioconnect Conference BioMed Event 2022 in Paris MADRID, Spain and CAMBRIDGE, Mass., Jan....
Robust efficacy - ORR 78%, of which 62% are CR/CRi 77% of CR/CRi lasting more than 6 months Longest remission beyond 1,000 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Enrollment in ALICE completed Dosi...
CBO joins from AIG Asset Management To lead global business strategy and US corporate initiatives from US base MADRID, Spain and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmac...
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...